

Get the latest on the Ascorbic Acid shortage in 2026. Learn what's causing supply issues, current costs, and how to find Vitamin C in stock.
If you've heard that Ascorbic Acid is in shortage — or you've experienced it firsthand at your pharmacy — this update covers everything you need to know. We'll explain which forms are affected, what's causing the supply problems, what it costs in 2026, and how to find it.
The answer depends on which form you need:
Injectable Ascorbic Acid (Ascor): Yes, the injectable form continues to experience supply disruptions in 2026. McGuff Pharmaceuticals, the sole manufacturer of the only FDA-approved Ascorbic Acid injection, has indicated that shipments are currently on hold. The company is actively working with the FDA to complete the remaining steps needed for product release.
OTC oral Ascorbic Acid: No shortage. Over-the-counter Vitamin C tablets, capsules, powders, and liquid drops remain widely available at pharmacies, grocery stores, and online retailers across the country.
The ASHP (American Society of Health-System Pharmacists) has tracked Ascorbic Acid injection shortages, listing it as an ongoing concern. If you rely on the injectable form, this is a situation worth monitoring closely.
The supply challenges trace back to several converging factors:
Ascor, manufactured by McGuff Pharmaceuticals, is the only FDA-approved injectable Ascorbic Acid on the U.S. market. When one company controls the entire supply, any manufacturing issue, regulatory requirement, or supply chain disruption creates an immediate shortage with no alternative sources.
In 2019, the FDA asked companies to stop distributing unapproved versions of Ascorbic Acid injection. Before that, patients had access to injectable Vitamin C from compounding pharmacies and other manufacturers. The FDA's action — while intended to ensure safety — significantly narrowed the available supply.
The FDA has an increasingly restrictive policy toward compounding pharmacies preparing products when an FDA-approved version exists. This means fewer compounding pharmacies can legally produce injectable Ascorbic Acid, further constraining supply.
Interest in high-dose IV Vitamin C therapy has grown substantially. Oncology practices, integrative medicine clinics, and critical care units all use injectable Ascorbic Acid, driving up demand at a time when supply is already limited.
For a deeper explanation, read our guide on why Ascorbic Acid is so hard to find in 2026.
Pricing varies dramatically depending on the form:
For ways to reduce your costs, see our complete guide to saving money on Ascorbic Acid.
A few developments are worth noting:
No new manufacturers have received FDA approval for injectable Ascorbic Acid as of early 2026, meaning the single-manufacturer situation persists.
Here are your best options for locating Ascorbic Acid right now:
For a detailed walkthrough, read our complete guide to finding Ascorbic Acid in stock.
The Ascorbic Acid shortage situation in 2026 is primarily an injectable supply issue. If you need oral Vitamin C, you're in good shape — it's widely available and affordable. If you need the injection, the situation is more challenging but not hopeless.
Stay proactive: use Medfinder to monitor availability, keep an open line of communication with your prescriber, and explore alternatives when possible. The supply picture may improve as McGuff Pharmaceuticals works to restore Ascor production, but in the meantime, having a backup plan is smart.
For more information on Ascorbic Acid's side effects and what to watch for, check our side effects guide.
You focus on staying healthy. We'll handle the rest.
Try Medfinder Concierge FreeMedfinder's mission is to ensure every patient gets access to the medications they need. We believe this begins with trustworthy information. Our core values guide everything we do, including the standards that shape the accuracy, transparency, and quality of our content. We’re committed to delivering information that’s evidence-based, regularly updated, and easy to understand. For more details on our editorial process, see here.